UPDATE: Oppenheimer Downgrades Nektar Therapeutics (NKTR) to Perform
Tweet Send to a Friend
(Updated - March 14, 2022 10:44 AM EDT)
Oppenheimer analyst Jay Olson downgraded Nektar Therapeutics (NASDAQ: NKTR) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jay Olson downgraded Nektar Therapeutics (NASDAQ: NKTR) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
